Evolution of the 4^th gen ADC Platform

Mechanistic-driven and computation-assisted design of next-gen ADC modules to fully realize therapeutic window for mono or dual-target ADCs.

Fit-for-target ADC design with Fantastic Four

Instead of conventional one-size-fit-all approach for suboptimal ADC development, we develop full suite of versatile and diversified carriers, conjugations, linkers and payloads for rational and fit-for-target ADC development.

Novel target and therapeutic combination

Innovative target selection and combination with deep understanding of target and disease biology to address unmet medical need and growing patient demands.

LyncBio establishes multiple proprietary ADC platforms with transformational.

We own two core technology platforms with fully independent intellectual property rights, boasting significant technical leadership and innovative potential. Relying on these platforms, we focus on major disease areas such as intestinal inflammation, multiple sclerosis, multiple solid tumor indications, and multiple myeloma, continuously advancing cutting-edge exploration and breakthroughs in drug research and development.